Efficacy and Mechanism Evaluation programme - Logo

Researcher-led remit

Quicklinks
 New funding stream for translational medicine
 Apply for Funding
The researcher-led workstream is currently open for outline applications.  This call will close at 1pm on 17 July 2012.
 Get Involved
Find out how to get involved with our work
 Resources
Useful links, FAQs and information to help with applications
 Join our mailing list
Latest News
 Treating severe fatigue in primary billary cirrhosis
 Lung volume reduction in COPD
 Provisional 2012 Commissioned Research Calls Announced
rss EME News Feed
twitter icon Follow NIHR on Twitter
 

 

Valid XHTML 1.0 Transitional

 

Plain English Campaign

 you are here › HomeAbout EME Researcher-led workstream remit

The EME researcher-led workstream is funded by the MRC.

The EME programme aims to support excellent clinical science with an ultimate view to improving health or patient care.

Broadly, while the Experimental Medicine schemes address the proof of concept and “can it work?” questions, the EME programme examines the efficacy of the intervention (“does it work?”) to the point where, in the example of a drug, a marketing authorisation could be sought or widespread use in healthcare supported. The safety of the intervention is also a subject for the EME programme. The HTA programme considers clinical and cost effectiveness ("is it worth it?").

The remit of the EME researcher-led workstream includes clinical trials and evaluative studies - in patients - which:

  • evaluate clinical efficacy of interventions (where proof of concept in humans has already been achieved);
  • add significantly to our understanding of biological or behavioural mechanisms and processes;
  • explore new scientific or clinical principles;
  • include the development or testing of new methodologies.

The EME programme WILL support:

  • research which seeks to determine definitive proof of clinical efficacy and size of effect, safety and possibly effectiveness;
  • studies that use validated surrogate markers as indicators of health outcome;
  • laboratory based, or similar, studies that are embedded within the main study, if relevant to the remit of the EME programme.

The EME programme WILL NOT support:

  • confirmatory studies or trials of incremental modifications and refinements to existing medical interventions;
  • proof-of-concept, proof-of-mechanism in humans, nor 'confidence in effect' studies;
  • research into 'global health', where 'global health' can be defined as 'areas where the health need is identified in developing countries (i.e. including diseases of developing countries), or where the health need does not yet exist in the UK but might in the future and the problem can be best addressed in developing countries';
  • research involving animals.

For eligibility criteria for the researcher-led workstream please visit: www.eme.ac.uk/resources/researcher_led_faqs.asp

The EME researcher-led workstream will support research proposals which are important to healthcare, from researchers based across the UK (England, Scotland, Wales and Northern Ireland).

 printer friendly version   share Share

The Efficacy and Mechanism Evaluation programme is funded by the MRC and NIHR, with contributions from the CSO in Scotland and NISCHR in Wales and the HSC R&D, Public Health Agency in Northern Ireland. It is managed by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) based at the University of Southampton.

University of Southampton - Logo